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Neurofibromin 1 (NF1) is a tumor suppressor gene encoding a Ras GTPase that 
negatively regulates Ras signaling pathways. Mutations in NF1 are linked to neurofi-
bromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. In terms 
of antitumor immunity, CD1d-dependent natural killer T (NKT) cells play an important 
role in the innate antitumor immune response. Generally, Type-I NKT cells protect (and 
Type-II NKT cells impair) host antitumor immunity. We have previously shown that CD1d-
mediated antigen presentation to NKT cells is regulated by cell signaling pathways. To 
study whether a haploinsufficiency in NF1 would affect CD1d-dependent activation of 
NKT cells, we analyzed the NKT-cell population as well as the functional expression of 
CD1d in Nf1+/− mice. Nf1+/− mice were found to have similar levels of NKT cells as wild-
type (WT) littermates. Interestingly, however, reduced CD1d expression was observed in 
Nf1+/− mice compared with their WT littermates. When inoculated with a T-cell lymphoma 
in  vivo, Nf1+/− mice survived longer than their WT littermates. Furthermore, blocking 
CD1d in vivo significantly enhanced antitumor activity in WT, but not in Nf1+/− mice. In 
contrast, a deficiency in Type-I NKT cells increased antitumor activity in Nf1+/− mice, but 
not in WT littermates. Therefore, these data suggest that normal NF1 expression impairs 
CD1d-mediated NKT-cell activation and antitumor activity against a T-cell lymphoma.
Keywords: neurofibromin 1, cD1d, natural killer T cells, T-cell lymphoma, antitumor immunity
inTrODUcTiOn
Neurofibromatosis type 1 is an autosomal-dominant disorder caused by a mutation in a tumor 
suppressor gene encoding the protein neurofibromin 1 (NF1) (1), affecting 1 in 3,500 individuals 
worldwide. NF1 is a p21ras (Ras) guanosine triphosphatase (GTP)-activating protein (GAP). It cata-
lyzes the hydrolysis of Ras-GTP, thus negatively regulating multiple Ras-dependent cellular signaling 
pathways (1). Mutations in NF1 are associated with many diseases, including hematopoietic cancers 
such as myeloid leukemia and diffuse plexiform neurofibromas (2). Extensive studies from human 
tissue analyses and mouse models have discovered that loss of heterogyzosity (LOH) of NF1 in 
Schwann cells and a heterozygous NF1 microenvironment are both important for the formation 
of neurofibromas (3, 4). LOH may also explain the localized formation of tumors in patients with 
neurofibromatosis type 1 (1).
2Liu et al. NF1 Impairs Innate Antitumor Immunity
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1901
Ras-dependent signaling pathways have been shown to be 
important for αβ T-cell positive selection (5). Because NF1 
is a negative regulatory GAP and highly expressed in leuko-
cytes (6), the absence of NF1 may affect T-cell development. 
An Nf1−/− mutation is embryonic lethal (1). Therefore, the 
method of Nf1−/− fetal liver reconstitution to immune-deficient 
mice, such as Rag1 KO mice, has been used to study T-cell devel-
opment in the absence of NF1 (7). Although an nf1 deficiency 
in mice increases T-cell numbers in both thymus and spleen, 
it also causes impaired proliferation of T  cells in response to 
in  vitro stimulation (7). Moreover, antigen receptor-induced 
proliferation is also defective in NF1-deficient peripheral 
B cells (8), implicating a positive (but unknown) role for NF1 in 
regulating B and T-cell receptor (TCR)-induced proliferation. 
An earlier study indicated that NF1 promotes thymocyte positive 
selection, but has no effect on negative selection (9). Increasing 
evidence also suggests that NF1 may function in other cellular 
processes besides negatively regulating Ras function (10). For 
example, the Sec14-homology domain of NF1 is involved in 
forming a bipartite lipid-binding module, and possibly binds 
to cellular glycerophospholipid ligands (11). The loss of NF1 in 
Drosophila causes a reduction in body size, which is rescued by 
increasing cAMP protein kinase (PKA) signaling; this suggests 
that NF1 may also regulate the cAMP signaling pathway in a 
GAP-independent manner (12).
Natural killer T (NKT) cells express both natural killer (NK) 
and T-cell markers. Unlike conventional T cells which recognize 
peptide antigens presented by MHC class I and II molecules, 
NKT  cells are activated by lipid antigens presented by the 
MHC class I-like molecule, CD1d. CD1d-deficient mice lack 
NKT  cells and NKT-cell development requires positive selec-
tion in the thymus, similar to conventional T-cell development 
(13). Ras/mitogen-activated protein kinase (MAPK) signaling 
pathways, which are important for αβ T-cell positive selection 
(5), have also been shown to be critical for NKT-cell develop-
ment (14). Furthermore, previous work from our laboratory 
has demonstrated that stimulation of MAPK pathways affects 
CD1d-mediated antigen presentation (15, 16). We have found 
that activation of the p38 pathway inhibits, whereas activation 
of ERK pathway increases, CD1d-mediated antigen presentation 
to NKT cells, likely through regulating the trafficking of CD1d 
molecules in antigen-presenting cells (15). In line with this, we 
reported that anthrax toxin inhibits CD1d-mediated antigen 
presentation by targeting the ERK pathway (16).
Based on TCR usage, NKT  cells can be divided into two 
groups: Type-I (invariant) and Type-II (other CD1d-restricted) 
NKT  cells. Type-I NKT (also called iNKT) cells express an 
invariant TCR α-chain rearrangement (Vα14Jα18 in mice and 
Vα24Jα18 in humans) that is associated with β-chains of limited 
diversity (Vβ8.2, Vβ7, and Vβ2 in mice; Vβ11 in humans). The 
glycolipid α-galactosylceramide (α-GalCer or PBS57), originally 
derived from a marine sponge, has been shown to be a specific 
activator of iNKT cells in a CD1d-dependent manner (17, 18). 
Type-II NKT  cells are less well-defined, due to a paucity of 
ligands identified that are recognized by these NKT cells (19, 20). 
However, by studying CD1d-deficient (lacking both Type-I and 
Type-II NKT cells) and Jα18-deficient mice (lacking only Type-I 
NKT cells), it is believed that Type-II NKT cells are similar to 
T  regulatory cells (Tregs) and are mostly immunosuppressive 
(21). In line with this idea, Type-II NKT cells have been shown 
to impair tumor immunosurveillance in a CD1d-dependent 
manner (22).
In the current study, we asked whether NF1, a negative 
regu lator of Ras/MAPK pathways, impacts CD1d-dependent 
antitumor activity by NKT  cells. Because an Nf1−/− mutation 
is embryonic lethal, a haploinsufficient (Nf1+/−) mouse model 
is commonly used for the study of NF1 function in  vivo. 
We analyzed NKT-cell activity as well as the functional expres-
sion of CD1d in Nf1+/− mice, in order to determine whether a 
haploinsufficiency in NF1 would affect the CD1d/NKT-cell axis 
in the context of NKT-cell-mediated antitumor activity.
MaTerials anD MeThODs
animals
Female C57BL/6 wildtype (WT) mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME, USA). Male Nf1+/− mice 
were kindly provided by Dr. Wade Clapp (Indiana University, 
Indianapolis, IN, USA). CD1d1 KO (CD1d1−/−) mice on the 
C57BL/6 background (23) were a kind gift from Dr. Luc Van 
Kaer (Vanderbilt University, Nashville, TN, USA). Jα18-deficient 
C57BL/6 mice were also obtained from Dr. Van Kaer, with 
permission from Professor M. Taniguchi (Chiba University, 
Chiba, Japan). All mice were bred in specific pathogen-free 
facilities at the Indiana University School of Medicine. Nf1+/− 
mice were backcrossed to CD1d1−/− mice or Jα18−/− to obtain 
Nf1+/−/CD1d1−/− and Nf1+/−/Jα18−/− mice, respectively. All mice 
were age- and sex-matched littermates, both males and females 
were utilized, and used in all experiments between 8 and 16 weeks 
of age. All animal procedures were approved by the Indiana 
University School of Medicine’s Institutional Animal Care and 
Use Committee.
cell lines
The Tap 2-deficient RMA/S T-cell lymphoma cell line was kindly 
provided by Drs. J. Yewdell and J. Bennink (National Institutes 
of Health, Bethesda, MD, USA). These cells were transfected 
with the pcDNA3.1-neo vector alone (RMA/S-V) or the vector 
with a mouse cd1d1 cDNA insert (RMA/S-CD1d) as previously 
described (23). MC57G–CD1d cells were generated by trans-
fecting the methylcholanthrene-induced fibrosarcoma cell line 
MC57G with a pSRα vector encoding mouse cd1d1 cDNA (a kind 
gift from Dr. S. Balk, Harvard University, Cambridge, MA, USA).
antibodies and reagents
Allophycocyanin (APC)-conjugated, PBS57-loaded, and 
unloaded CD1d tetramers were provided by the NIH Tetramer 
Core Facility (Atlanta, GA, USA). APC-, Phycoerythrin (PE)-, 
and fluorescein isothiocyanate (FITC)-conjugated monoclonal 
antibodies (mAb) against murine NK  cell-, B-cell- or T-cell-
specific markers, including NK1.1, MHC class II, CD11c, B220, 
CD1d (1B1), CD4, CD8, and TCRβ, were purchased from 
BD Biosciences (San Diego, CA, USA). PE/Cy7-conjugated 
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anti-CD21 and PerCP/Cy5.5-conjugated anti-CD23 were from 
Biolegend (San Diego, CA, USA). The mouse CD1d-specific mAb 
1H6 generated by our laboratory has been previously described 
(24). The isotype control mAb TW2.3 was kindly provided by 
Drs. J. Yewdell and J. Bennink (NIH, Bethesda, MD, USA). 1H6 
and TW2.3 hybridoma supernatants were purified by immobi-
lized protein A agarose beads for in vivo use.
Flow cytometry
Thymocytes and splenocytes were harvested using standard 
procedures. Liver mononuclear cells (LMNCs) were harvested 
as described previously (25). To obtain bone marrow-derived 
dendritic cells (BMDCs), bone marrow cells obtained from 
mouse femurs and tibias were cultured in the presence of IL-4 
(10  ng/mL) and GM-CSF (10  ng/mL) for 7  days. For flow 
cytometry analyses, single-cell suspensions of all indicated 
cell types were prepared, and 1 ×  106 cells were incubated at 
4°C for 30 min with various mAb as indicated. The cells were 
washed three times with HBSS containing 0.1% bovine serum 
albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA). All cells 
were fixed with 1% paraformaldehyde in PBS and analyzed on a 
FACSCalibur or LSRII (Becton Dickinson, San Jose, CA, USA).
T-cell stimulation assays
Bone marrow-derived dendritic cells from Nf1+/− mice and their 
littermates were incubated with the mouse Type-I NKT hybri-
doma N38-2C12 (26) or Type-II NKT hybridoma N37-1A12 
(27) [both hybridomas kindly provided by Dr. K Hayakawa (Fox 
Chase Cancer Center, Philadelphia, PA, USA)]. 5 ×  104 hybri-
doma cells and 5 ×  105 BMDCs were added to triplicate wells 
in 96-well microtiter plates for 24 h. Secreted IL-2 levels in the 
supernatants were measured by ELISA.
Western Blot analysis
Thymocytes and splenocytes were lysed, separated on a 10% 
SDS-PAGE gel and then transferred to a polyvinylidene dif-
luoride (PVDF) membrane (Merck Millipore, Billerica, MA, 
USA). The blot was then probed with phospho-JNK1/2 or 
ERK1/2-specific antibodies (Cell Signaling Technology, Inc., 
Danvers, MA, USA), and developed using chemiluminescence 
prior to exposure on film. The same membrane was then 
stripped and reprobed with total JNK1/2- or ERK1/2-specific 
antibodies (Cell Signaling Technology Inc.). Images were 
quantified using ImageJ (1.37v; National Institutes of Health, 
Bethesda, MD, USA).
In Vitro stimulation of nKT cells
Liver mononuclear cells (2.5 × 105 cells/well) from Nf1+/− mice or 
WT littermates were cocultured with α-GalCer-pulsed MC57G–
CD1d cells (5 ×  105 cells/well) in triplicate wells of a 96-well 
microtiter plate. After culture at 37°C for 48 h, the supernatants 
were collected for the analysis of NKT-cell production of IFN-γ, 
IL-4, and IL-13 by ELISA.
Tumor inoculation
Nf1+/−, CD1d1−/−, Nf1+/−/CD1d1−/−, Jα18−/−, Nf1+/−/Jα18−/−, and 
their WT littermates were inoculated intraperitoneally (i.p.) 
with 5 × 105 RMA/S-V or RMA/S-CD1d cells in 500-µL IMDM 
media supplemented with 5% FBS. The mice were monitored 
for up to 60 days posttumor inoculation, as previously described 
(23). To block CD1d in  vivo, the mice were injected i.p. with 
50 μg/mouse of purified mouse CD1d-specific antibody (1H6) 
or isotype control mAb in PBS on days 1, 5, 10, and 20 post-
tumor inoculation.
statistics
Graphs were generated and statistics calculated using GraphPad 
Prism 6 (GraphPad Software, La Jolla, CA, USA). The mean 
of triplicates of a representative assay is shown with error bars 
representing the SEM, using Student’s t-test analyses. For the sta-
tistical analysis of survival rate, the log-rank test was performed. 
A p-value < 0.05 was considered significant.
resUlTs
increased JnK and erK activation  
in Nf1+/− Mice
Previous reports have shown increased Ras-GTP levels in 
unstimulated thymocytes from Nf1+/− mice when compared 
with WT mice (7). In our study, we also observed elevated ERK 
phosphorylation in splenocytes and thymocytes when they were 
stimulated with Phorbol 12-myristate 13-acetate (Figure  1A; 
Figures S7A,B in Supplementary Material), suggesting elevated 
activation of the Ras/ERK pathway in Nf1+/− mice. Compared 
with their WT littermates, Nf1+/− mice were also found to have 
elevated JNK activation in the spleen and thymus (Figure  1B; 
Figures S7C,D in Supplementary Material). We did not observe 
any hyperactivation of p38 in the thymus or spleen from Nf1+/− 
mice (data not shown). These data indicate that elevated Ras-GTP 
activity causes hyperactivation of the ERK and JNK pathways in 
Nf1+/− mice.
comparable inKT-cell Population  
in WT and Nf1+/− Mice
Previous studies have suggested that an NF1 deficiency increases 
the number of immature and mature conventional T cells in vivo, 
but reduces cell proliferation in response to TCR and IL-2 stim-
ulation in vitro (7). NF1 promotes thymocyte positive selection, 
a process that is also required for NKT-cell development (9, 28). 
To determine if an NF1 deficiency affects iNKT-cell develop-
ment, we compared the iNKT-cell populations in thymus, 
spleen, and liver from Nf1+/− mice to those from WT littermates. 
We found there were comparable levels of iNKT cells in WT and 
Nf1+/− mice (Figure 2), suggesting that a haploinsufficiency in 
NF1 has a minimal effect on NKT-cell development and their 
numbers in the periphery.
lower cD1d expression on BMDcs  
from Nf1+/− Mice
Although a haploinsufficiency in NF1 did not seem to affect 
iNKT-cell development, we found that BMDCs from Nf1+/− 
mice expressed lower levels of CD1d (but similar amounts of 
FigUre 2 | Comparable numbers of iNKT cells in wildtype (WT) and Nf1+/− mice. (a) Thymocytes, splenocytes, and liver mononuclear cells from Nf1+/− mice and 
WT littermates were stained with α-GalCer-loaded CD1d tetramers and a TCR-β-specific antibody for the identification of iNKT cells, identified in the upper right 
quadrant. (B) Percentages (upper) and total numbers (lower) of iNKT cells are summarized for the thymus, spleen and liver. Pooled data from three independent 
experiments are shown. Each dot represents an individual mouse. The data are plotted as mean ± SEM.
FigUre 1 | Increased activation of ERK and JNK in the spleen and thymus of Nf1+/− mice. Splenocytes and thymocytes were treated with Phorbol 12-myristate 
13-acetate (100 ng/mL) for 30 min. The cells were then lysed and resolved on a 10% SDS-PAGE gel for the detection of phosphorylated and total ERK1/2  
(a) and JNK1/2 (B) expression by Western blot analysis. The relative levels of phosphorylated ERK1/2 and JNK1/2 compared with the total respective proteins  
were quantified by densitometry. Combined results from multiple experiments are shown in the bar graphs. The data are plotted as the mean ± SD. *p < 0.05.
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MHC class I and II) on the cell surface compared with WT 
BMDCs (Figure  3A; Figure S1 in Supplementary Material). 
Furthermore, similar to the reduced CD1d expression observed 
in Nf1+/− BMDCs, there was also a significant decrease in the 
splenic B220+CD21hiCD23intCD1dhi population in Nf1+/− mice 
(Figures  3B,C). These cells express a high level of CD21 and 
low to intermediate levels of CD23, suggesting they are marginal 
zone B (MZB) cells. We also analyzed DCs (MHC II+ CD11c+) 
and macrophages (MHC II+ F4/80+) for CD1d expression, but 
there were no differences between WT and Nf1+/− mice (data 
not shown). Although BMDCs from Nf1+/− mice expressed 
less CD1d on their surface, they were similar to WT BMDCs 
in their ability to activate both Type-I and Type-II NKT-cell 
hybridomas (Figure 3D). Interestingly, thymocytes from both 
WT and Nf1+/− mice express similar levels of CD1d and have 
a comparable ability in stimulating NKT  cells (Figure S8 in 
FigUre 3 | Lower CD1d expression on cells from Nf1+/− mice. (a) Bone marrow-derived dendritic cells (BMDCs) from Nf1+/− and wildtype (WT) mice were fixed and 
stained with the anti-CD1d mAb, 1B1. CD1d-specific staining from a representative Nf1+/− mouse (dotted line) was overlaid with that of a WT littermate (solid line). 
(B) Splenocytes from Nf1+/− mice or WT littermates were stained with MHC II-, B220-, CD21-, CD23-, and CD1d-specific antibodies. MHC II+ cells were gated and 
further analyzed for B220, CD21, CD23, and CD1d expression by flow cytometry. The circled population corresponds to B220+CD21hiCD23intCD1dhi splenocytes. 
Combined results from multiple experiments are shown in (c). Each dot represents an individual mouse. ***p < 0.001. (D) BMDCs from Nf1+/− mice or WT 
littermates were cocultured with the NKT-cell hybridomas, N38-2C12 and N37-1A12. The activation of NKT cells by BMDCs was determined by ELISA, measuring 
IL-2 secretion in the supernatants. The relative levels of IL-2 production in Nf1+/− BMDCs compared with WT (WT = 1) are indicated. Combined results from multiple 
experiments are shown. The data are plotted as the mean ± SEM. Each dot represents an individual mouse.
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Supplementary Material); this suggests that a haploinsufficiency 
in NF1 does not alter the positive selection of NKT cells in the 
thymus. Overall, we conclude that a haploinsufficiency in NF1 
reduces CD1d surface expression, but the decrease in CD1d 
expression in Nf1+/− cells is likely still above the normal thresh-
old level necessary to activate NKT cells. This may help explain 
why Nf1+/− mice have a similar level of iNKT cells in vivo as their 
WT littermates.
increased activation of inKT  
cells from Nf1+/− lMncs
Because there was decreased CD1d expression on APCs from 
Nf1+/− mice, we next wanted to find out whether NKT cells from 
Nf1+/− mice were functionally normal in  vitro and in  vivo. To 
test iNKT-cell function in vitro, LMNCs were cocultured with 
CD1d-expressing MC57G cells (derived from histocompatible 
H-2b mice) in the presence of the iNKT-cell ligand, α-GalCer. 
FigUre 4 | Increased activation of liver iNKT cells from Nf1+/− mice. Liver 
mononuclear cells (LMNCs) from individual Nf1+/− mice or wildtype (WT) 
littermates were cocultured with MC57G–mCD1d cells in the presence of 
α-GalCer for 48 h. Activation of iNKT cells was measured by IFN-γ (a) and 
IL-4 (B) production into the supernatants. ***p < 0.001. (c) MC57G–mCD1d 
cells were cocultured with LMNCs from WT mice in the presence or absence 
of the murine CD1d-specific antibody, 1H6, for 48 h. Production of IFN-γ into 
the supernatants was measured by ELISA. The data are shown as the 
mean ± SEM. The results are representative of three independent 
experiments.
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LMNCs from Nf1+/− mice were more responsive to CD1d-
mediated antigen presentation than those from their WT litter-
mates (Figures 4A,B). The addition of an anti-CD1d antibody 
blocked the activation of iNKT cells (Figure 4C), demonstrating 
that the NKT-cell activation was CD1d-specific. In contrast to 
antigen-specific activation, when LMNCs from Nf1+/− mice 
were stimulated with anti-CD3 and anti-CD28 antibodies, they 
secreted a similar level of cytokines as their WT littermates 
(Figure S2 in Supplementary Material). Thus, these data dem-
onstrate that iNKT  cells (but not conventional T  cells) from 
Nf1+/− mice are more activated than those from WT littermates 
upon exogenous lipid Ag stimulation in vitro.
To determine whether the NF1 haploinsufficiency would 
affect NKT-cell function in vivo, we injected the iNKT-cell ligand 
α-GalCer to Nf1+/− mice and their WT littermates. At different 
time points, sera were harvested and circulating IL-4 and IFN-
γ were measured. Nf1+/− mice produced similar levels of these 
cytokines as their WT littermates (Figure S3 in Supplementary 
Material). Therefore, these results suggest that iNKT  cells are 
functionally normal in Nf1+/− mice.
Nf1+/− Mice Bearing rMa/s Tumors 
surviving longer Than WT Mice
Because we observed decreased CD1d expression but increased 
iNKT-cell activity in  vitro in Nf1+/− mice, it was important to 
determine what the impact of a haploinsufficiency of NF1 would 
be on CD1d-dependent antitumor activity. Previous reports 
have suggested that Nf1+/− mice are predisposed to developing 
multiple cancers after 1 year of age, and thus have a shorter life 
span compared with WT mice (1). To address this question, 
we inoculated Nf1+/− mice and their WT littermates with the 
RMA/S T cell lymphoma transfected with an empty vector or 
the murine cd1d1 cDNA (23). They were then observed for 
tumor incidence and survival rate. Surprisingly, Nf1+/− mice had 
a better survival rate and longer median survival time (MST) 
than their WT littermates when they were challenged with either 
CD1d-positive or CD1d-negative RMA/S tumor cells although, 
in this experiment, the difference between Nf1+/− and WT mice 
was not statistically significant (Figure S4 in Supplementary 
Material). Thus, in terms of survival, the antitumor activity in 
Nf1+/− mice exceeds that of their WT littermates.
Blocking cD1d In Vivo enhancing 
antitumor activity in WT But not  
Nf1+/− Mice
Our previous studies have shown enhanced survival in CD1d-
deficient mice when they were inoculated with RMA/S T-cell 
lymphoma cells (23). It was possible that the reduced CD1d 
expression in Nf1+/− mice altered host antitumor activity. To test 
this hypothesis, Nf1+/− and WT mice were treated with an anti-
CD1d antibody or isotype control at various times before and 
after they were inoculated with RMA/S-CD1d cells. Blocking 
CD1d expression by a CD1d-specific antibody significantly 
enhanced antitumor activity in WT mice. The CD1d-specific 
antibody treatment in Nf1+/− mice also increased the survival 
rate of tumor-bearing mice. Although reproducible, the dif-
ference was not statistically significant in this experiment 
(Figures 5A–C). In a parallel experiment, CD1d was also geneti-
cally deleted from Nf1+/− mice by back-crossing Nf1+/− mice to 
CD1d1−/− mice. Thus, Nf1+/−, CD1d1−/−, Nf1+/−/CD1d1−/−, and 
WT mice were inoculated with RMA/S-CD1d cells, WT mice 
had the lowest survival rate among these four different strains of 
mice (Figures 5D,E). As was observed when CD1d was blocked 
by antibody in vivo, deleting CD1d genetically from WT (but 
not Nf1+/−) mice significantly enhanced their survival rate 
(Figure 5F). Therefore, reduced CD1d expression in Nf1+/− mice 
very likely contributes to host antitumor activity in this model 
system.
nF1-haploinsufficient Type-i (But not  
Type ii) nKT cells suppressing antitumor 
immunity In Vivo
CD1d-deficient mice lack both Type-I and Type-II NKT cells, 
whereas Jα18−/− mice only have Type-II NKT  cells (29). To 
determine the impact of NF1 on the antitumor activity of Type-I 
and Type-II NKT  cells, Nf1+/− mice were crossed with Jα18−/− 
mice to generate Nf1+/−/Jα18−/− mice. These mice, together 
with their WT, Nf1+/− and Jα18−/− littermates were inoculated 
with RMA/S-CD1d cells. While WT and Jα18−/− mice died at 
a similar rate, as we observed in multiple experiments, Nf1+/− 
mice survived significantly longer than their WT littermates 
(Figures  6A,C,D). Interestingly, Nf1+/−/Jα18−/− mice had the 
highest survival rate among the four experimental groups 
(Figures 6A,C). Thus, the deletion of Type-I NKT cells in Nf1+/− 
mice significantly enhanced survival (Figure  6D), which sug-
gests NF1-haploinsufficent Type-I NKT cells may actually impair 
antitumor activity. However, as Nf1+/−/Jα18−/− mice survived 
much longer than their Jα18−/− littermates, this would indicate 
FigUre 5 | Blocking CD1d in vivo enhancing antitumor activity in wildtype (WT) (but not Nf1+/−) mice. (a) Nf1+/− mice (black symbols) and their WT littermates (white 
symbols) were treated i.p. with 50 µg of anti-CD1d antibody 1H6 (triangles) or isotype control (circles) on day 1, and days 5, 10, and 20 posttumor inoculation. The 
mice were inoculated i.p. with 5 × 105 RMA/S-CD1d cells on day 0 and survival was monitored for up to 60 days posttumor inoculation. Pooled data from three 
independent experiments are shown. N = 14–15 per group. The median survival time (MST) and percent survival on the final day were determined and summarized 
in (B). Statistical analyses of the survival curves between the different groups are shown in (c). The p-values were based on a log-rank test comparing the survival 
curves of the indicated two groups of mice. S, significant, p < 0.05; NS, not significant, p > 0.05. (D) Nf1+/− (black circles), Nf1+/−/CD1d1−/− (black triangles) 
CD1d1−/− (white triangles), and their WT littermates (white circles) were inoculated with 5 × 105 RMA/S-CD1d cells on day 0 and their survival was monitored for up 
to 60 days posttumor inoculation. Pooled data from three independent experiments are shown. N = 7–13 per group. The MST and percent survival on the final day 
were determined and summarized in (e). Statistical analyses of the survival curves between the different groups are shown in (F). The p-values were based on a 
Log-rank test comparing the survival curve of the indicated two groups of mice. S, significant, p < 0.05; NS, not significant, p > 0.05.
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that a haploinsufficiency of NF1 also results in a reduction of the 
immunosuppressive activity of Type-II NKT cells. In fact, Nf1+
/−/Jα18−/− and Nf1+/−/CD1d1−/− mice had similar survival rates 
posttumor inoculation (Figures 6B–D); this suggests that NF1-
haploinsufficent Type-II NKT cells in Nf1+/−/Jα18−/− mice are less 
able to suppress antitumor immunity as compared with WT.
DiscUssiOn
Neurofibromatosis type 1 is a disease caused by mutations in 
the NF1 gene, a negative regulator of the Ras signaling pathway. 
Elevated Ras/ERK activation has been reported in Nf1+/− mice 
and reconstituted NF1−/− mice, as well as cells from NF1 patients 
(7, 30). Hyperactivation of the Ras/ERK pathway was also 
confirmed in the current study by the detection of increased 
phospho-ERK in the thymus and spleen of Nf1+/− mice. Although 
hyperactivation of the Ras/ERK pathway has been reported to 
be associated with a defect in NKT-cell development (31), we 
did not observe any defect in NKT-cell development in Nf1+/− 
mice. Instead, our work has demonstrated that NKT cells from 
Nf1+/− mice actually have enhanced CD1d-dependent activation, 
compared with those from their WT littermates. We observed 
similar levels of circulating cytokines in Nf1+/− mice after in vivo 
treatment with α-GalCer, even though APCs from Nf1+/− mice 
expressed lower levels of CD1d compared with their WT lit-
termates. This may be explained by the increased responsiveness 
of NKT cells in vitro.
On the other hand, the reduced CD1d expression found in 
BMDCs from Nf1+/− mice suggests that NF1 positively regulates 
CD1d expression. It is worthwhile to point out that this effect 
might be due to in vitro cultures, as we did not observe a dif-
ference in CD1d expression in splenic DCs. It is well-known 
that NF1 is a negative regulator of the Ras/MAPK pathway (1). 
We not only observed hyperactivation of the Ras/ERK pathway 
but also detected elevated Ras/JNK pathway activation in the 
thymus and spleen of Nf1+/− mice. Daginakatte et al. (32) also 
reported increased JNK activation in Nf1+/− microglia cells, but 
not Nf1−/− astrocytes, which likely contributed to the increased 
proliferation of Nf1+/− microglia cells in that study. Consistent 
with our findings, they also did not observe increased p38 activa-
tion in these tissues (32). Our results are particularly interesting 
because we found that blocking the JNK pathway increases 
(and activation of JNK decreases) CD1d-mediated antigen 
presentation (Liu et al., manuscript in preparation). In contrast, 
we previously reported that elevated ERK activation enhances 
CD1d-mediated antigen presentation during a viral infection by 
FigUre 6 | NF1-haploinsufficient Type-I (but not Type-II) NKT cells suppressing antitumor immunity in vivo. (a) Nf1+/− (black circles), Nf1+/−/Jα18−/− (black triangles), 
Jα18−/− (white triangles), and WT littermates (white circles) were inoculated with 5 × 105 RMA/S-CD1d cells on day 0 and survival was monitored for up to 60 days 
posttumor inoculation. Pooled data from two independent experiments are shown. N = 15–21 per group. (B) Nf1+/−/Jα18−/− and Nf1+/−/CD1d1−/− mice were 
inoculated with RMA/S-CD1d cells and their survival was monitored as shown in (a). Pooled data from two independent experiments are shown. N =18 per group. 
The MST and percent survival on the final day were determined and summarized in (c). Statistical analyses of the survival curves between the different groups are 
shown in (D). The p-values were based on a Log-rank test comparing the survival curve of the indicated two groups of mice. S, significant, p < 0.05; NS, not 
significant, p > 0.05.
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regulating intracellular CD1d trafficking (15). Thus, it is very 
likely that the reduction of CD1d expression in Nf1+/− APCs is 
an outcome of the combined regulation of multiple signaling 
pathways as a consequence of the NF1 haploinsufficiency. It is 
worthwhile to mention that we did not observe any difference in 
CD1d recycling (Figure S5 in Supplementary Material) or CD1d 
distribution by confocal microscopy between BMDCs from 
Nf1+/− or WT littermates (data not shown). This suggests that 
the reduced CD1d expression on the cell surface of Nf1+/− APCs 
is not due to modified CD1d intracellular trafficking caused by 
an NF1 haploinsufficiency.
Marginal zone B cells, which express a high level of CD1d, 
are reduced in Nf1+/− mice. Moreover, it is known that Notch2 
is indispensable to MZB development (33). A recent report 
suggests that Notch is the effector of NF1 in neurological tissue 
(34). Thus, a haploinsufficiency of NF1 may affect Notch2 and 
thereby alter MZB development. However, NF1 may have other 
unknown functions, not just as a Ras-GAP. A 2,839-amino-
acid protein, NF1 contains two major functional domains: a 
Ras-GAP-related domain (Ras-GRD) and a Sec14-interactive 
domain. The Sec14-interactive domain is involved in forming 
a bipartite lipid-binding module and possibly binds to a cel-
lular glycerophospholipid ligand (11). Further investigations are 
needed to determine how NF1 regulates CD1d expression.
We observed increased antitumor activity in Nf1+/− mice 
compared with their WT littermates. Although the differences 
were not always statistically significant, Nf1+/− mice consistently 
survived longer than their WT littermates. Treatment with 
a CD1d-specific mAb has shown to protect mice from tumor 
metastasis by several groups (22, 35, 36). It has been suggested 
that the CD1d mAb may block the activation of “immunosup-
pressive” Type-II NKT  cells (22). Crosslinking CD1d by a 
specific mAb can also activate antigen-presenting cells, such 
as DCs, to produce the proinflammatory cytokines IL-12 and 
IFN-γ (35, 36). Reduced CD1d expression in Nf1+/− mice may 
be somewhat like CD1d-deficient mice (or CD1d mAb-treated 
mice), in that there is a dysfunction in (or reduced activity of) 
“immunosuppressive” Type-I NKT cells; this could explain the 
increased antitumor activity observed in Nf1+/− mice. It is also 
consistent with the findings that blocking CD1d in vivo enhanced 
antitumor activity in WT but Nf1+/− mice. In the current study, 
WT and Jα18−/− mice died at similar rates and CD1d1−/− mice 
survived longer than WT mice. The results suggest that Type-I 
NKT  cells have little impact on antitumor activity whereas 
Type-I NKT cells are immunosuppressive in this model system 
(Figure  7). Nf1+/−/Jα18−/− mice survived much longer than 
Nf1+/− littermates, suggesting that NF1-haploinsufficient Type-I 
NKT  cells, although demonstrating increased activity in  vitro, 
suppressed antitumor activity in vivo.
Type-I NKT cells can directly destroy tumor cells, especially 
those expressing CD1d on their surface, by performing cytolysis 
via perforin, granzyme B, Fas ligand (FasL), and TRAIL (37). 
Type-I NKT cells can also suppress the function of myeloid-derived 
suppressor cells (MDSC) and suppressive IL-10-producing neu-
trophils, to enhance antitumor immunity (20). Type-I NKT cells 
are capable of producing both Th1 and Th2 cytokines (38). The 
avidity and stability of antigen/TCR complex determines the type 
of cytokine production. Strong antigen/TCR interaction causes 
FigUre 7 | A working model illustrating that neurofibromin 1 (NF1) plays 
distinct roles in regulating the antitumor activity of Type-I and Type-II 
NKT cells in vivo. NF1 reduces the immunosuppressive activity of Type-I 
NKT cells, as NF1-haploinsufficient Type-I NKT cells suppress antitumor 
immunity. In contrast, NF1 expression upregulates CD1d levels and enhances 
the immunosuppressive activity of Type-II NKT cells. In line with this, a 
haploinsufficiency in NF1 causes a reduction in CD1d expression and 
decreases the immunosuppressive activity of Type-II NKT cells, augmenting 
antitumor immunity.
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NKT  cells to produce Th1 cytokines, whereas weak antigen/
TCR interaction results in Th2 cytokines from NKT cells (39). 
Th1-biased and IFNγ-producing Type-I NKT cells greatly boost 
antitumor immunity (20). On the other hand, Type-I NKT cells 
have been reported to be immunosuppressive by supporting Tregs 
and/or suppressing tumor-specific CD8+ T cells (40, 41). In the 
current study, the reduced CD1d expression observed in Nf1+/− 
mice may further cause Type-I NKT cells to become Th2-biased 
and thereby suppress the antitumor activity of CTL and NK cells. 
In conclusion, NF1-haploinsufficient Type-I NKT cells are more 
immunosuppressive compared with WT Type-I NKT  cells, 
through a currently unknown mechanism.
In contrast, Nf1+/−/Jα18−/− mice survived much longer than 
their Jα18−/− littermates, indicating that Type-II NKT  cells 
in Nf1+/− mice are not as immunosuppressive as WT Type-II 
NKT  cells. Nf1+/−/Jα18−/− mice survived at a similar rate as 
Nf1+/−/CD1−/− mice, further confirming that Type-II NKT cells in 
Nf1+/− mice are not immunosuppressive. Our work suggests that 
NF1 is required for the immunosuppressive activity of Type-II 
NKT  cells. The reduced CD1d expression in Nf1+/− mice may 
functionally alter Type-II NKT cells, moving from suppressing 
to enhancing antitumor activity.
A recent publication has suggested that Tregs are also impor-
tant in the balance of antitumor activity involving Type-I/Type-II 
NKT cells (29). We did not observe any changes in Tregs in our 
studies (data not shown). Further studies are needed to investi-
gate tumor immunosurveillance by Type-I/Type-II NKT cells as 
well as Tregs in Nf1+/− mice.
One question raised from our tumor challenge study is the 
identity of the effector cells that are responsible for removing the 
tumor cells in vivo. Because the RMA/S cell line is Tap-2 deficient, 
they express a very low level of MHC I molecules on their surface 
(42). Thus, the effector cells for eliminating RMA/S cells are 
unlikely to be CD8+ cytotoxic T cells. NKT cells have also been 
shown to exhibit cytotoxicity activity against CD1d+ cells (23). 
However, because Nf1+/− mice are more resistant to both CD1d+ 
and CD1d− RMA/S cells, it is unlikely that the sole effector cells 
are NKT cells. Another population of cytotoxic cells that could 
play a role here are NK cells. RMA/S cells are highly susceptible to 
NK cell-mediated lysis (43). We speculate that Type-I and Type-II 
NKT cells may impact the function of NK cells in the RMA/S 
tumor model (Figure 7). On the other hand, the cytolytic activity 
of NK cells is also regulated by many signaling pathways (44). It 
has been reported that NK cells from vav-1 (a GEF)-deficient mice 
have reduced cytotoxicity (45), suggesting that NK cell activity 
may be impacted by changes in Ras/MAPK pathways. However, 
in the current study, we did not observe increased cytotoxicity by 
NK cells in Nf1+/− mice (Figure S6 in Supplementary Material). 
Of further interest, a recent report suggests that the inoculation 
of mice with RMA/S cells causes NK cell anergy and escape from 
antitumor immunity (46). Importantly, NK  cell anergy only 
occurs in the tumor proximal environment and is likely due to 
impaired ERK activation downstream of activating receptors on 
NK cells (46). It is possible that NK cells in Nf1+/− mice may be 
compensated for by reduced ERK phosphorylation and rescue 
of MAPK/ERK signaling in the tumor microenvironment; thus, 
Nf1+/− mice would exhibit an increase in antitumor immunity 
and have enhanced survival. Further studies will be focused on 
how NF1 regulates the antitumor activity of NKT and NK cells 
in Nf1+/− mice.
Neurofibromas are derived from a broad range of cells, includ-
ing hyperproliferative Schwann cells, fibroblasts, mast cells and 
perineural cells (47). Loss of heterogyzosity of NF1 in Schwann 
cells and a heterozygous NF1 microenvironment are both impor-
tant for the formation of neurofibromas (3). Schwann cells have 
been shown to express CD1d and can activate NKT cells to secrete 
anti-inflammatory cytokines (48). We speculate that the absence of 
NF1 in Schwann cells from NF1 patients may cause a deficiency in 
CD1d expression. It would be interesting to study the tumor immu-
nosurveillance activity of Type-I and Type-II NKT cells within the 
neurofibroma microenvironment, where Schwann cells are NF1-
deficient. Further studies are necessary to understand the role of 
the CD1d/NKT-cell axis in NF1-dependent disease progression.
In summary, we have found reduced CD1d expression but 
increased antitumor activity in a haploinsufficiency model of 
NF1. This is likely due to reduced immunosuppressive activity 
by Type-II NKT  cells, rather than by an increase in antitumor 
activity by Type-I NKT cells. The results support the hypothesis 
that NF1 regulates CD1d-mediated NKT-cell activation and con-
sequent antitumor activity (Figure 7). Future work will focus on 
investigating how NF1 may regulate the antitumor activity of 
NKT cells. Our study may therefore provide mechanistic support 
to target NF1 to improve CD1d/NKT-cell-based immunetherapy.
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